BAM15

BAM15 functions as a mitochondrial protonophore, meaning it carries protons (H+) across the inner mitochondrial membrane in a way that dissipates the proton gradient that mitochondria normally use to drive ATP synthesis. Under normal conditions, the electron transport chain pumps protons from the matrix into the intermembrane space as electrons flow from NADH and FADH2 to oxygen, creating a chemiosmotic gradient of roughly 150-180 mV across the inner membrane. ATP synthase (Complex V) uses the inward flow of protons back through its F0 channel to drive the mechanical rotation that phosphorylates ADP into ATP. Protonophores like BAM15, DNP, FCCP, and CCCP are lipophilic weak acids that can shuttle protons across the membrane independently of ATP synthase, effectively short-circuiting the gradient and causing the electron transport chain to run at high rate while producing less ATP per oxygen consumed (Kenwood et al., 2014). The energy that would have gone into ATP synthesis is instead dissipated as heat, which is why uncouplers increase metabolic rate and oxygen consumption and why sustained exposure produces fat loss — the body oxidizes more substrate to maintain cellular ATP levels, and the excess energy leaves as thermogenesis. What distinguishes BAM15 from DNP is selectivity for the inner mitochondrial membrane. DNP is a weak acid with a pKa around 4, and its protonated and deprotonated forms both partition readily into biological membranes, which means DNP uncouples mitochondria but also depolarizes the plasma membrane and other intracellular compartments. Plasma membrane depolarization is a significant problem because it alters cellular excitability, disrupts sodium-potassium gradients, and contributes to the tachycardia, hyperthermia, and cardiac arrhythmias that cause DNP deaths. BAM15, by contrast, was selected in the Kenwood et al. screen specifically for its ability to uncouple isolated mitochondria at concentrations that did not depolarize the plasma membrane of whole cells (Kenwood et al., 2014). The structural basis of this selectivity is thought to involve BAM15's specific pKa, lipophilicity, and the geometry of its furazanopyrazine scaffold, which allows efficient shuttling across the high-potential inner mitochondrial membrane but inefficient shuttling across the lower-potential plasma membrane (Salamoun & Childers, 2020). The functional consequence in cells and animals is that BAM15 raises mitochondrial oxygen consumption and heat production without the cardiovascular and neurological toxicity signature of DNP at comparable uncoupling intensity. Downstream of the uncoupling event, BAM15 produces several metabolic changes that are relevant to its proposed therapeutic applications. Increased mitochondrial respiration at the electron transport chain means more substrate is oxidized per unit time, which reduces the accumulation of reducing equivalents (NADH, FADH2) that would otherwise generate reactive oxygen species through reverse electron transport at Complex I. This explains why BAM15 paradoxically reduces oxidative stress despite increasing oxygen consumption — the faster the ETC cycles, the less time electrons spend stalled at reduction-prone sites (Alexopoulos et al., 2020). Lower ATP:ADP ratio activates AMP-activated protein kinase (AMPK), which promotes fatty acid oxidation, glucose uptake, and mitochondrial biogenesis, and inhibits lipogenesis and cholesterol synthesis. Increased substrate demand pulls free fatty acids out of adipose tissue and into mitochondria for beta-oxidation, producing the fat-loss effect in rodent obesity models. Improved insulin sensitivity likely arises from a combination of reduced intramyocellular and hepatic lipid content, AMPK activation, and possibly direct effects on the insulin signaling cascade (Alexopoulos et al., 2020; Axelrod et al., 2022). In the liver specifically, BAM15 reduces de novo lipogenesis and steatosis in diet-induced NASH models, which is the basis for early interest in mitochondrial uncouplers as potential NAFLD/NASH therapies. The key nuance about the mechanism that is often missed in consumer-facing writeups is that uncoupling is not inherently beneficial — it is beneficial in a specific window of intensity. Too little uncoupling and there is no metabolic effect. Too much uncoupling and cells run out of ATP, mitochondrial membrane potential collapses, the permeability transition pore opens, cytochrome c is released into the cytoplasm, and apoptosis or necrosis follows. The therapeutic window is defined by how much uncoupling a tissue can tolerate before ATP synthesis becomes rate-limiting for essential cellular functions. In rodent studies with BAM15, that window appears wider than with DNP, but "wider" is not the same as "wide," and there are no human data establishing where the edge is in people.

BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014). The full chemical name is (2-fluorophenyl)-(6-(2-fluorophenyl)amino)amine, molecular weight 338.3 g/mol, and the molecule was identified through a high-throughput screen designed to find uncouplers that behave differently from the classical reference compound 2,4-dinitrophenol (DNP). DNP raises metabolic rate and causes rapid fat loss in animals and humans but has a catastrophically narrow therapeutic window, with hyperthermia, cataracts, peripheral neuropathy, and fatal overdoses well documented in the 1930s weight-loss literature and in modern case series of bodybuilders and diet pill users who source DNP as a research chemical (Grundlingh et al., 2011). BAM15 was explicitly designed to improve on DNP by restricting uncoupling activity to mitochondria and not the plasma membrane, theoretically producing the metabolic benefit — increased substrate oxidation, reduced reactive oxygen species, improved insulin sensitivity — without the cardiovascular and thermoregulatory toxicity that makes DNP untenable as a drug. If you are on this page because you heard BAM15 called "a safe DNP" on a forum or podcast, you should finish this entry before you do anything else. BAM15 is a research chemical. There are zero published clinical trials in humans as of April 2026, zero FDA-approved indications, zero pharmacokinetic or toxicology studies in people, and zero manufacturers producing it under pharmaceutical-grade quality standards for human use. Every dose anyone has ever taken has come from a research-chemical vendor with no regulatory oversight. The preclinical animal data are genuinely exciting — BAM15 reverses diet-induced obesity in mice at doses that appear well tolerated, improves hepatic steatosis in rodent NASH models, lowers blood glucose, improves insulin sensitivity, and reduces ROS generation without the hyperthermia and death that DNP produces at comparable efficacy doses. But "better than DNP in mice" is an extremely low bar, and the gap between "promising in rodents" and "safe in humans at a predictable dose" is exactly where hundreds of drug candidates have died over the last two decades. This entry is a complete summary of what BAM15 actually does mechanistically, what the preclinical evidence shows, what it does not show, why there are no human trials despite a decade of academic interest, and what the realistic landscape looks like for anyone considering experimenting with it. We will talk about the pharmacology in enough detail that you can have an informed conversation with a physician about why you should probably not be using this compound, and we will also be honest that a subset of people will use it anyway, in which case the harm-reduction information below — dose ranges reported in self-experimenters, signs of mitochondrial toxicity, interactions with other metabolic agents, and the reasons no one has been able to bring this drug to a Phase 1 trial despite its theoretical advantages — becomes the most important part of the page. Uncoupler chemistry is one of the few mechanisms in metabolism that cannot be meaningfully replicated by training, diet, or lifestyle intervention. Exercise, cold exposure, fasting, and caloric restriction all activate mitochondrial biogenesis and uncoupling protein expression (UCP1, UCP2, UCP3), which is the body's own physiological version of uncoupling. Those interventions should be fully optimized before anyone looks at a chemical protonophore, because physiological uncoupling through brown adipose tissue activation, exercise-induced mitochondrial adaptation, and UCP upregulation delivers a substantial fraction of the metabolic benefit with none of the drug-risk profile. BAM15 exists in the conversation because people want a pill version of cold exposure and cardio. That desire is legitimate, but the pill does not yet exist in a form any reasonable clinician would recommend.

IUPAC Name

N-(2-nitro-4-(trifluoromethyl)phenyl)-[4-(2-hydroxy-3,3-dimethylbutoxy)phenyl]methanamine

CAS Number

203203-79-6

Molecular Formula

C17H19N3O4

Molecular Mass

357.35 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get BAM15 Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Data Completeness

88%

Research Credibility